Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Exp Cell Res. 2014 Feb 17;322(2):415–424. doi: 10.1016/j.yexcr.2014.02.010

Fig. 2.

Fig. 2

HeLa cells are refractory to the Bcl-2/Bcl-xL inhibitor ABT-737. A. HeLa cells or RS4;11 cells were treated with vehicle (0.1% DMSO) (100% viability) or treated with ABT-263 (0.01-10 μM) for 72 h followed by assesment for cell viability by MTT assay. Results given are mean ± standard deviation (n = 6). The right panel shows immunoblot analysis of indicated proteins in HeLa versus RS4;11 cells. B. HeLa cells were treated with vehicle (0.1% DMSO) (100% viability) or treated with vinblastine (0.1-100 nM) alone or with 1 μM ABT-263 for 72 h followed by assesment for cell viability by MTT assay. Results given are mean ± standard deviation (n = 6).